CAR-ving away OX40L with engineered Tregs.

Jonathan S Maltzman1,2

  • 1Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Science Immunology
|November 1, 2024
PubMed
Summary

Chimeric antigen receptor T regulatory cells (CAR-Tregs) engineered with OX40 Ligand (OX40L) show potential for treating autoimmune diseases and preventing organ transplant rejection. This approach offers a novel strategy for immune tolerance induction.